Production (Stage)
Cognition Therapeutics, Inc.
CGTX
$0.3217
$0.02347.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 16.35% | -16.35% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 28.46% | -25.86% | |||
| Operating Income | -28.46% | 25.86% | |||
| Income Before Tax | -8.14% | 21.08% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -8.14% | 21.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -8.14% | 21.08% | |||
| EBIT | -28.46% | 25.86% | |||
| EBITDA | -28.54% | 25.91% | |||
| EPS Basic | 21.82% | 28.63% | |||
| Normalized Basic EPS | 23.75% | 26.87% | |||
| EPS Diluted | 20.72% | 29.36% | |||
| Normalized Diluted EPS | 23.75% | 26.87% | |||
| Average Basic Shares Outstanding | 38.38% | 10.54% | |||
| Average Diluted Shares Outstanding | 38.38% | 10.54% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||